Aortic Valve Market and its Growth Prospect in the Near Future

The insulin delivery device market size is projected to reach $15.6 billion by 2022, growing at a CAGR 6.6% between 2016-2022.

The increasing prevalence of diabetes, growing geriatric population, increasing prevalence of obesity, technological of drug delivery devices and increasing awareness of diabetic care are driving the growth of the market.

In terms of type, the insulin delivery device market is segmented into insulin pen, insulin syringe, insulin pump and others. The insulin pen segment accounted for the major market share in the global market in 2015, and the insulin pump segment is expected to witness the highest growth during 2016-2022.

Request for a sample of this research report: 

Insulin pen needle has single use, although many diabetic patients re-use needle for delivery of insulin. The re-use of needle could lead to bacterial growth on the needle, risk of lipohypertrophy and risk of breaking fine tip of needle. Similarly, the risk associated with jet injectors are accuracy of insulin dosage and improper injection. Improper injection of insulin can lead to altered absorption level of insulin in the blood stream and bruising. Hence, these risks and complications associated with delivery devices are inhibiting the growth of the insulin delivery device market.

Some of the key companies operating in the insulin delivery device market include Novo Nordisk A/S, Medtronic PLC, Abbott Laboratories, Eli Lilly and Company, Insulet Corporation, Sanofi S.A., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Animas Corporation, B. Braun Melsungen AG, and Ypsomed Holdings AG.

Read More…